Genentech, a member of the Roche Group, has exercised its final option for an exclusive target under a collaboration agreement with Affimed N.V. to develop and commercialize novel NK cell engager-based immunotherapeutics generated from Affimed’s ROCKplatform to treat multiple cancers. The target selection triggers an undisclosed milestone payment from Genentech. “The designation of the final target marks another milestone for the collaboration, which brings   together Genentech’s deep underst...